Galanin immunoreactivity is increased in the nucleus basalis of Meynert in Alzheimer's disease

• Published in: Annals of neurology Vol. 28; no. 2; p. 157
• Main Authors: Beal, M F, MacGarvey, U, Swartz, K J
• Format: Journal Article
• Language: English
• Published: United States 01.08.1990
• Subjects: Aged; Alzheimer Disease - metabolism; Amino Acids - analysis; Catecholamines - analysis; Choline O-Acetyltransferase - analysis; Female; Galanin; Humans; Male; Neuropeptides - analysis; Neurotransmitter Agents - analysis; Peptides - analysis; Radioimmunoassay; Substantia Innominata - chemistry
• ISSN: 0364-5134
• DOI: 10.1002/ana.410280207

A depletion of large cholinergic neurons in the nucleus basalis of Meynert is a consistent finding in Alzheimer's disease (AD). The nucleus basalis of Meynert also contains interneurons and afferents that may modulate its functioning. In the present study we examined neurochemical markers for neuropeptides, amino acid neurotransmitters, and monoaminergic neurotransmitters in postmortem samples of the nucleus basalis in 16 control subjects and 30 patients with AD. There were no significant changes in glutamate, aspartate, taurine, gamma-aminobutyric acid (GABA), and catecholamines; however, concentrations of serotonin, 5-hydroxyindoleacetic acid, and 5-hydroxytryptophol were significantly reduced. Choline acetyltransferase activity was significantly reduced, consistent with previous reports. Galanin immunoreactivity was significantly increased twofold in the patients with AD, but there were no significant changes in substance P, somatostatin, or neuropeptide Y immunoreactivity. Since galanin inhibits acetylcholine release, and produces cognitive deficits in animals, increased galanin immunoreactivity in the nucleus basalis of Meynert in AD may contribute to the cognitive deficits that characterize the illness.